From cutting-edge research to compassionate patient practice, neurologists and neurosurgeons from Columbia and Weill Cornell Medicine are at the forefront of developing and applying the most advanced approaches to treat debilitating conditions affecting the brain and spine. With a broad range of focus on neurodegenerative and neurovascular disorders to malignant tumors, our innovative and advanced care is leading to new treatment options and enabling patients to achieve the best possible outcomes.
Featured Updates
Results from a new multi-center study, led by oncologists at NewYork-Presbyterian and Weill Cornell Medicine, has described for the first time a key biomarker – absolute lymphocyte count (ALC) – that has the potential to predict therapeutic response to chimeric antigen receptor (CAR) T-cell immunotherapy for patients with relapsed/refractory multiple myeloma. While this FDA-approved treatment is widely used, until now there has not been a way to predict whether B-cell maturation antigen (BCMA) CAR T-cell therapy would elicit a good response.
The Latest
Pediatric Neurology & Neurosurgery
Crossing Specialty Lines for Rare Genetic Neurocutaneous Conditions
